Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI

Abstract Challenges remain for clinicians over balancing the efficacy of active antithrombotic therapy and simultaneous bleeding reduction in patients. The clinical data of 347 patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) were retrospectively analyz...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yong-zhe Guo, Zi-wen Zhao, Shu-mei Li, Liang-long Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c428ba58c6174d438a65548fa754bc3d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c428ba58c6174d438a65548fa754bc3d
record_format	dspace
spelling	oai:doaj.org-article:c428ba58c6174d438a65548fa754bc3d2021-12-02T15:09:06ZClinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI10.1038/s41598-021-96606-y2045-2322https://doaj.org/article/c428ba58c6174d438a65548fa754bc3d2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96606-yhttps://doaj.org/toc/2045-2322Abstract Challenges remain for clinicians over balancing the efficacy of active antithrombotic therapy and simultaneous bleeding reduction in patients. The clinical data of 347 patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) were retrospectively analyzed. On the basis of the given tirofiban, the patients were assigned into three different dose groups: high dose group (group H), medium dose group (group M), and low dose group (group L). The tirofiban efficacy was evaluated in terms of major adverse cardiovascular event (MACE) parameters and lab endpoints, including platelet count and function. The tirofiban safety was assessed by the occurrence of bleeding events. The patients were followed up for 1 month after the PCI. No significant difference in MACE events was evident among these groups (p > 0.05). Groups H and M reported an obvious reduction in platelet count (p < 0.05 for both) and an increased platelet inhibition rate (p < 0.05 for both). Group H showed a higher rate of total bleeding events than the other groups (Group H vs. Group M: 34.4% vs. 16.5%; Group H vs. Group L: 34.4% vs. 10.3%; p < 0.05 for both). A proper administration of a low dose of tirofiban may be a superior alternative in treating ACS patients, which can produce a similar favorable clinical outcome and a decrease in bleeding complication.Yong-zhe GuoZi-wen ZhaoShu-mei LiLiang-long ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yong-zhe Guo Zi-wen Zhao Shu-mei Li Liang-long Chen Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI
description	Abstract Challenges remain for clinicians over balancing the efficacy of active antithrombotic therapy and simultaneous bleeding reduction in patients. The clinical data of 347 patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) were retrospectively analyzed. On the basis of the given tirofiban, the patients were assigned into three different dose groups: high dose group (group H), medium dose group (group M), and low dose group (group L). The tirofiban efficacy was evaluated in terms of major adverse cardiovascular event (MACE) parameters and lab endpoints, including platelet count and function. The tirofiban safety was assessed by the occurrence of bleeding events. The patients were followed up for 1 month after the PCI. No significant difference in MACE events was evident among these groups (p > 0.05). Groups H and M reported an obvious reduction in platelet count (p < 0.05 for both) and an increased platelet inhibition rate (p < 0.05 for both). Group H showed a higher rate of total bleeding events than the other groups (Group H vs. Group M: 34.4% vs. 16.5%; Group H vs. Group L: 34.4% vs. 10.3%; p < 0.05 for both). A proper administration of a low dose of tirofiban may be a superior alternative in treating ACS patients, which can produce a similar favorable clinical outcome and a decrease in bleeding complication.
format	article
author	Yong-zhe Guo Zi-wen Zhao Shu-mei Li Liang-long Chen
author_facet	Yong-zhe Guo Zi-wen Zhao Shu-mei Li Liang-long Chen
author_sort	Yong-zhe Guo
title	Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI
title_short	Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI
title_full	Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI
title_fullStr	Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI
title_full_unstemmed	Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI
title_sort	clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in acs patients undergoing pci
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c428ba58c6174d438a65548fa754bc3d
work_keys_str_mv	AT yongzheguo clinicalefficacyandsafetyoftirofibancombinedwithconventionaldualantiplatelettherapyinacspatientsundergoingpci AT ziwenzhao clinicalefficacyandsafetyoftirofibancombinedwithconventionaldualantiplatelettherapyinacspatientsundergoingpci AT shumeili clinicalefficacyandsafetyoftirofibancombinedwithconventionaldualantiplatelettherapyinacspatientsundergoingpci AT lianglongchen clinicalefficacyandsafetyoftirofibancombinedwithconventionaldualantiplatelettherapyinacspatientsundergoingpci
_version_	1718387900640395264

Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI

Ejemplares similares